Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
0.15 AUD | 0.00% | 0.00% | -25.00% |
04-11 | Bigtincan Holdings Logs AU$30 Million Revenue in Fiscal Q3; Shares Surge 19% | MT |
03-18 | Bigtincan Holdings Limited(ASX:BTH) dropped from S&P/ASX All Ordinaries Index | CI |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
Strengths
- The company is in a robust financial situation considering its net cash and margin position.
- The stock, which is currently worth 2024 to 0.61 times its sales, is clearly overvalued in comparison with peers.
- The company's share price in relation to its net book value makes it look relatively cheap.
- For the last twelve months, analysts have been gradually revising upwards their EPS forecast for the upcoming fiscal year.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
- Analysts' price targets are all relatively close, reflecting good visibility on the company's valuation.
Weaknesses
- According to Standard & Poor's' forecast, revenue growth prospects are expected to be very low for the next fiscal years.
- Low profitability weakens the company.
- For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
- The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
- For the last four months, EPS estimates made by Standard & Poor's analysts have been revised downwards.
- The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
- Over the past twelve months, analysts' opinions have been revised negatively.
- Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.
Ratings chart - Surperformance
Sector: Biotechnology & Medical Research
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-25.00% | 61.78M | - | ||
+29.77% | 49.46B | B- | ||
+1.00% | 42.58B | B | ||
+50.47% | 42.49B | A | ||
-5.26% | 29.09B | C | ||
+13.68% | 26.61B | B- | ||
-22.99% | 18.64B | B | ||
+8.22% | 13.16B | B+ | ||
+32.41% | 12.55B | C+ | ||
-1.62% | 11.98B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- BTH Stock
- Ratings Bigtincan Holdings Limited